Gout, a painful form of inflammatory arthritis, is poised to become a larger public health concern in the coming decades. According to projections, the global prevalence of gout is expected to rise significantly over the next 25 years, driven by aging populations, obesity, and lifestyle factors. In the United States alone, over 9 million people have been diagnosed with the disease, and an additional 44 million people have uric acid levels above the normal range, putting them at risk. Current treatments, while effective for some, are often limited by tolerability issues, including severe gastrointestinal problems, kidney toxicity, and cardiovascular risks, leading to poor patient adherence.
XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company, is developing a potential solution. The company’s proprietary drug candidate, XORLO™, is a formulation of oxypurinol designed to overcome the historically poor oral absorption of the compound. By utilizing a liposomal delivery system, XORLO aims to provide high bioavailability and rapid absorption, allowing for effective uric acid reduction at lower total daily doses. This approach could minimize the toxic-level exposure and severe side effects associated with high-dose traditional therapies. XORTX believes XORLO offers a differentiated treatment option for gout patients who cannot tolerate or do not respond adequately to existing xanthine oxidase inhibitors.
The company is making strides toward bringing XORLO to market. It recently announcing the launch of drug material and tablet manufacturing to support a planned two-part clinical study, XRX-OXY-102. This study is being advanced based on positive prior clinical results and discussions with the U.S. Food and Drug Administration (FDA). Contract production of pure oxypurinol drug substance has already begun, and XORTX is working with its manufacturing partner to produce commercial drug batches.
Regulatory progress is also underway. XORTX is working toward a new drug application submission for XORLO, with a new Investigational New Drug (IND) application prepared for submission to the FDA in the fourth quarter of 2026. The IND describes the clinical development plan, and if the two-part clinical trial is successful, XORTX intends to request a pre-NDA meeting and prepare an NDA submission while engaging in pre-commercialization activities. The company is targeting an NDA submission in approximately one year and estimates a market opportunity of $700 million annually for XORLO.
“Our planned IND submission to the FDA next quarter is a defining step for the XRx-026 program,” said Allen Davidoff, Co-CEO of XORTX. “It reflects the strength of our prior clinical results and moves us closer to potentially offering gout patients a differentiated treatment option.”
For investors and industry observers, XORTX’s progress highlights the growing demand for better gout therapies. With millions of patients inadequately served by current options, a successful new entrant could capture significant market share. However, the company still faces the inherent risks of clinical development and regulatory approval. The outcome of the XRX-OXY-102 trial and the FDA review will be critical in determining whether XORLO can become a viable alternative. As gout prevalence continues to climb, the need for innovative, well-tolerated treatments becomes increasingly urgent, making XORTX’s efforts one to watch.
